SB0886 • 2026

Discounted Drug Pricing Study

Passed Legislature

This bill passed both chambers and reached final enrollment, even if later executive action is not shown here.

Sponsor: Rodriguez
Last action: 2026-03-13
Official status: Senate - Died in Health Policy
Effective date: 2026-07-01

Plain English Breakdown

The exact details of how pharmacy benefits managers, wholesalers, and distributors will be involved in discounted drug pricing under the 340B program are not clearly specified in the provided text.

Discounted Drug Pricing Study

This bill requires the Agency for Health Care Administration to study discounted drug pricing under the 340B program and report its findings by January 31, 2027.

What This Bill Does

Requires the Agency for Health Care Administration to conduct or contract a detailed fiscal impact study on discounted drug prices under the 340B Drug Pricing Program.
The study will examine requirements for drug manufacturers to sell drugs at no more than the 340B price if they are on the Medicaid preferred drug list and covered by the 340B program.
It also looks into how pharmacy benefits managers, wholesalers, and distributors could be involved in these lower prices under the 340B program.
Requires the agency to provide its findings to the Governor, President of the Senate, and Speaker of the House by January 31, 2027.

Who It Names or Affects

The Agency for Health Care Administration
Drug manufacturers
Medicaid pharmacies
Pharmacy benefits managers
Wholesalers and distributors

Terms To Know

340B Drug Pricing Program: A federal program that allows certain organizations to buy drugs at discounted prices.
Medicaid preferred drug list: A list of drugs recommended for use by Medicaid patients because they are considered safe and effective.

Limits and Unknowns

The bill does not specify what actions will be taken based on the study's results.
It is unclear if this bill will become law since it died in Health Policy committee.

Bill History

2026-03-13 Senate
• Died in Health Policy
2026-01-13 Senate
• Introduced
2025-12-16 Senate
• Referred to Health Policy; Appropriations Committee on Health and Human Services; Appropriations
2025-12-12 Senate
• Filed

Official Summary Text

Discounted Drug Pricing Study; Requiring the Agency for Health Care Administration to conduct or contract for a specified study; requiring the agency to provide the results to the Governor and the Legislature by a specified date, etc.

Current Bill Text

Read the full stored bill text

Florida Senate
-
2026

SB 886

By
Senator Rodriguez

40-01022-26 2026886__
1 A bill to be entitled
2 An act relating to discounted drug pricing study;
3 requiring the Agency for Health Care Administration to
4 conduct or contract for a specified study; providing
5 requirements for the study; requiring the agency to
6 provide the results to the Governor and the
7 Legislature by a specified date; providing an
8 effective date.
9
10 Be It Enacted by the Legislature of the State of Florida:
11
12 Section 1.
(1)

The Agency for Health Care Administration

13
shall conduct or contract for a detailed fiscal impact study to

14
determine the feasibility of implementing the following

15
provisions relating to discounted drug prices under the 340B

16
Drug Pricing Program:

17
(a)1.

Requiring drug manufacturers to sell a drug to

18
Medicaid pharmacies at no more than the 340B Drug Pricing

19
Program discounted price if the drug is:

20
a.

On the Medicaid preferred drug list as described in s.

21
409.912(5), Florida Statutes.

22
b.

A covered drug under the 340B Drug Pricing Program.

23
2.

Authorizing drug manufacturers to deliver drugs sold in

24
accordance with subparagraph 1. to the purchasing Medicaid

25
pharmacy by any method used by the drug manufacturer.

26
3.

If a drug manufacturer sells a drug in accordance with

27
subparagraph 1. to a Medicaid pharmacy at the 340B Drug Pricing

28
Program discounted price and such discounted price is higher

29
than the state Medicaid negotiated price, requiring the drug

30
manufacturer to pay a rebate to the state equal to the

31
difference between the discounted price and the state Medicaid

32
negotiated price.

33
(b)

Requiring pharmacy benefits managers participating in

34
the Medicaid program to pay a Medicaid pharmacy the 340B Drug

35
Pricing Program discounted price plus the professional

36
dispensing fee as determined under rule 59G-4.251, Florida

37
Administrative Code, as amended, for any drug that is on the

38
Medicaid preferred drug list as described in s. 409.912(5),

39
Florida Statutes, and that is a covered drug under the 340B Drug

40
Pricing Program.

41
(c)1.

Requiring drug wholesalers and distributors to sell a

42
drug to a Medicaid pharmacy at the 340B Drug Pricing Program

43
discounted price if the drug is:

44
a.

On the Medicaid preferred drug list as described in s.

45
409.912(5), Florida Statutes.

46
b.

A covered drug under the 340B Drug Pricing Program.

47
2.

Prohibiting drug wholesalers and distributors from

48
changing an existing pricing model or program that is in place

49
with a Medicaid pharmacy by exempting a drug described in

50
paragraph (a) from the pricing model or program or by

51
referencing such drug in any way in the pricing model or

52
program.

53
(d)

Requiring Medicaid pharmacies to provide a covered drug

54
under the 340B Drug Pricing Program at the discounted price only

55
to Medicaid recipients.

56
(2)

The agency shall submit the results of the study to the

57
Governor, the President of the Senate, and the Speaker of the

58
House of Representatives by January 31, 2027.

59 Section 2. This act shall take effect July 1, 2026.